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Rabbit modelMajor limitations of calcium phosphate cements (CPCs) are their relatively slow degradation rate and the
lack of macropores allowing the ingrowth of bone tissue. The development of self-setting cement foams
has been proposed as a suitable strategy to overcome these limitations. In previous work we developed a
gelatine-based hydroxyapatite foam (G-foam), which exhibited good injectability and cohesion, intercon-
nected porosity and good biocompatibility in vitro. In the present study we evaluated the in vivo perfor-
mance of the G-foam. Furthermore, we investigated whether enrichment of the foam with soybean
extract (SG-foam) increased its bioactivity. G-foam, SG-foam and non-foamed CPC were implanted in a
critical-size bone defect in the distal femoral condyle of New Zealand white rabbits. Bone formation
and degradation of the materials were investigated after 4, 12 and 20 weeks using histological and
biomechanical methods. The foams maintained their macroporosity after injection and setting in vivo.
Compared to non-foamed CPC, cellular degradation of the foams was considerably increased and
accompanied by new bone formation. The additional functionalization with soybean extract in the
SG-foam slightly reduced the degradation rate and positively inﬂuenced bone formation in the defect.
Furthermore, both foams exhibited excellent biocompatibility, implying that these novel materials
may be promising for clinical application in non-loaded bone defects.
 2014 Acta Materialia Inc. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Calcium phosphate ceramics are frequently used as bone substi-
tutes. In general, they are biocompatible, bioactive and integrate
well in bony host tissue [1]. They are used as granules, blocks or
cements either to reconstruct bone defects after trauma or to aug-
ment weak bone prior to implant placement. The advantages of
using moldable calcium phosphate cements (CPCs) instead of
pre-formed blocks or granules are the option to apply them using
a minimally invasive surgical procedure and better adaptability to
the defect geometry.
However, a major disadvantage of CPC is the lack of macropores
to allow cell colonization and vessel formation. This hinderscell-mediated material resorption, which is particularly required
for apatite cements given their low physicochemical solubility
[2]. The development of self-setting cement foams has been pro-
posed as a suitable strategy to overcome this limitation. Mechani-
cal foaming of the cement paste by incorporating a biocompatible
foaming agent has been demonstrated to be a promising approach
[2]. Our group was the ﬁrst to use albumen (i.e. egg white) as a
foaming agent [3]. We conﬁrmed the suitability of the resulting
macroporous self-setting foam as a bone ﬁller in vivo in rabbits,
clearly demonstrating that the macroporous structure was main-
tained after implantation and that the foam resorbed signiﬁcantly
more rapidly compared to non-foamed cements [4]. Although the
albumen foam was replaced by newly formed bone, the albumen
did, however, evoke a moderate immunogenic reaction [4]. More
recently, our group demonstrated that gelatine could also be used
efﬁciently as a foaming agent for CPC [2,5]. Gelatine is denatured
collagen, the main protein in bone extracellular matrix, and has
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novel calcium phosphate foams containing gelatine exhibited good
osteogenic properties in vitro [7]. Therefore, one aim of the present
study was to evaluate the performance of this novel foam under
in vivo conditions.
Taking a further developmental step, we also combined
gelatine-based foams with soybean-derived compounds [7]. The
rationales behind the application of soybean extract were its good
foaming capabilities and the improvement of injectability of the
cements [7]. Even more important is that soybean extract contains
the isoﬂavones genistin and daidzin, which in contact with plasma
are activated to genistein and daidzein [8,9]. These activated iso-
ﬂavones, so-called phytoestrogens, are considered to provoke a
beneﬁcial effect on bone metabolism by acting similarly to estro-
gen [10]. They also elicit anti-inﬂammatory effects, including the
inhibition of the T- and B-cell responses and natural killer cell cyto-
toxic activity [10,11]. These effects could potentially decrease the
inﬂammatory response to an implant and stimulate bone forma-
tion. Santin et al. conﬁrmed this by demonstrating decreased
osteoclast formation and activity, and increased osteoblast differ-
entiation after stimulating these cells with soybean-based bioma-
terial granules [11]. In agreement with these results, our group
demonstrated that the enrichment of the novel hydroxyapatite/
gelatine foam with soybean extract favored osteoblast activity
and differentiation in vitro [7]. It was also demonstrated in a rabbit
model that polymeric hydrogels which were functionalized with
soybean extract showed good biocompatibility and high bone
regeneration potential [12,13].
Based on our previous work, the aim of this study was to
evaluate the in vivo performance of injectable self-setting
hydroxyapatite/gelatine foams with and without soybean-extract
enrichment. Using a critical-size defect in the rabbit femur, we
investigated the time course of material degradation and new bone
formation in comparison with non-foamed CPC.2. Materials and method
2.1. Preparation of materials
We synthesized three types of material: non-foamed CPC,
hydroxyapatite/gelatine foam (G-foam) and soybean-enriched
hydroxyapatite/gelatine foam (SG-foam) as we described previ-
ously in detail [7].
The calcium phosphate powder, which was the basis for all the
materials, consisted of 98 wt.% of a-tricalcium phosphate (a-TCP)
and 2 wt.% of precipitated hydroxyapatite (pHA, Merck, Darmstadt,
Germany). The a-TCP was prepared by heat treatment of a stoichi-
ometric mixture of CaCO3 and CaHPO4 (both Sigma-Aldrich,
Gillingham, UK) at 1400 C, followed by quenching in air, to avoid
the unwanted beta phase, and ﬁnally milled to obtain the powder.
The liquid phase was a 2.5 wt.% Na2HPO4 water solution (Merck,
Darmstadt, Germany). To prepare the G- and SG-foam, the liquid
phase was prepared by dissolving respectively 15 and 5 wt.% of
bovine type B gelatine (Bloom 250, Rousselot, Courbevoie, France)
in the 2.5 wt.% Na2HPO4 (Merck, Germany) water solution at 50 C
in a water bath. The liquid phase of the SG-foam was additionally
enriched with 20 wt.% of soybean extract, which was obtained
from soybean ﬂour (Inﬁnity Foods, Brighton, UK) using a co-solvent
defatting system at 50 C according to a previously described pro-
cess [7].
For the in vivo test, the cement powder and the Na2HPO4 salt
were sterilized using 25 kGy gamma radiation, while the polymeric
components of the liquid phase were sterilized as dried powders
using 8 kGy gamma radiation to avoid their denaturation. To
prepare the sterile liquid phase, all the sterile components weredissolved under a sterile hood in previously autoclaved distilled
water. The cement foaming process was performed under sterile
conditions in the operating theater using a water bath at 50 C.
First, 2 ml of the liquid phase were foamed for 1 min at
11,000 rpm using a customized hand mixer. Second, after foaming,
the cement powder was incorporated in the liquid foam and fur-
ther mixed using a sterile spatula, preventing foam disruption,
until complete homogenization of the paste.
The liquid to powder (L/P) ratio for the preparation of the
G- and SG-foam was adjusted to 0.75 ml g1 and 0.55 ml g1,
respectively. For the non-foamed CPC, the liquid phase consisted
of a 2.5 wt.% Na2HPO4 water solution without any polymer incor-
poration and was mixed by spatula with the cement powder at
an L/P ratio of 0.50 ml g1. At these L/P ratios, all three pastes pre-
sented complete injectability and good cohesion in distilled water.
Finally, for orthotopic implantation, the pastes were ﬁlled into
sterile syringes and manually injected into the bone defect. In all
cases, the time elapsed from the liquid-phase foaming until the
implantation by injection was <5 min. In contrast, for subcutane-
ous implantation the pastes were injected in Teﬂon molds and
allowed to set for 12 days in Ringer’s solution (0.9% NaCl) at
37 C to obtain disks of 5 mm diameter and 3 mm thickness. Prior
to implantation, the pre-set disks were sterilized using 25 kGy
gamma radiation.
2.2. Animal study design and surgery
The experimental procedures were performed in accordance
with the international regulations for the care and use of labora-
tory animals, and were approved by the German government
(Regierungspräsidium Tübingen, No. 837). 60 skeletally mature
female New Zealand white rabbits (age: 28 weeks; mean weight:
3.8 ± 0.5 kg) were randomly divided into three groups (n = 20 per
group), corresponding to the three tested materials: CPC, G-foam
and SG-foam. Each material was implanted in both the left and
right femur.
After premedication with a subcutaneous injection of atropine
sulfate (Atropinsulfat Braun 0.5 mg, B.Braun, Melsungen,
Germany), the rabbits were anesthetized using an intravenous
injection of a mixture of ketamine hydrochloride (Ketamin 10%,
WDT, Garbsen, Germany) and xylazine hydrochloride (Rompun,
2%, Bayer Health Care, Grenzach, Germany). The lateral condyle
of the left and right femur was exposed and a cylindrical defect
of 5 mm diameter and 10 mm depth was drilled. Bone debris were
removed from the drill hole by washing with sterile saline solution
prior to injection of the materials. The muscle and the subcutane-
ous soft tissue were sutured. A pre-set cement disk (5 mm diame-
ter, 3 mm thickness) of the same material composition was placed
subcutaneously before closing the skin. Immediately after surgery,
the animals were allowed full weight bearing and freedom of
movement.
Six animals were euthanized after 4 weeks and seven animals
after 12 and 20 weeks, respectively, per material group. Both
femurs as well as the subcutaneous samples were recovered for
analysis. One femur was evaluated histologically and the other
by biomechanical testing as described below.
2.3. Assessment of the foam-setting reaction in vivo
The progress of the setting reaction in vivo was assessed by
determining the crystalline phases present in the foams 1 month
after orthotopic implantation. The samples, embedded in methyl
methacrylate resin (Technovit VLC 7200, Heraeus Kulzer GmbH,
Wehrheim, Germany), were analyzed using X-ray diffraction
(XRD; PANalytical, X’Pert PRO Alpha-1, Almelo, Netherlands) by
scanning in Bragg–Brentano geometry using copper Ka radiation.
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4-100, counting time 200 s per point, voltage 45 kV and intensity
40 mA.
2.4. Histological evaluation
For histomorphometry, the distal part of the femur and the cor-
responding subcutaneous implants were explanted immediately
after euthanasia of the rabbits. The samples were ﬁxed in buffered
4% formalin, dehydrated using increasing alcohol concentrations
and embedded in methyl methacrylate. Then, 80 lm sections were
prepared as described previously [14]. These bone sections were
stained using Paragon (Paragon C&C; New York, USA) or Giemsa
while the subcutaneous samples were stained using Giemsa. Histo-
logical slices were examined using light microscopy (Axiophot;
Zeiss, Oberkochen, Germany). For quantitative histological analy-
sis, the point-counting method (P1000 points per sample) was
performed at 100-fold magniﬁcation [15]. The relative amounts
of the remaining material, newly formed bone and soft tissue were
determined. As control, the intact bone was evaluated in the same
manner. Histological evaluation was performed in a blinded
manner.
2.5. Biomechanical evaluation
To investigate the mechanical competence of the treated defect
region, we performed a compression test. Immediately after
explantation, a 3 mm slice was cut out of the distal part of the left
femur in the middle and perpendicular to the axis of the cylindrical
bone defect. A compression load was applied to the defect region in
a material-testing machine (Zwick Z010, Zwick, Ulm, Germany)
using a steel indenter of 4 mm diameter at a constant velocity of
2 mmmin–1 and a preload of 0.5 N. The force was recorded contin-
uously using a 500 N load cell (KAF-TC, AST Zwick, Ulm, Germany).
The test was stopped automatically at a maximum force of 400 N
or maximum indentation of 1.5 mm. The stiffness of the sample
was analyzed using the software program of the testing machine
(testXpert, Zwick, Ulm, Germany). From the linear region of
the load (F)–deﬂection (d) curve, the stiffness S was calculated
(S = F/d). For comparison, the intact bone was evaluated in the
same manner. Additionally, we determined the compression
stiffness of non-implanted cements, which were injected in Teﬂon
molds having the same size as the bone defect, in the same way
after in vitro setting for 12 days in Ringer’s solution.
2.6. Statistics
Data analysis was performed using the statistic-analyzing
program JMP (Version 5.0.1.2, SAS Institute, Cary, NC, USA). The
Wilcoxon Rank Sum test was performed to determine signiﬁcant
differences between the material groups. To determine signiﬁcant
differences within a material group over time, the Kruskal–Wallis
test was performed. The level of signiﬁcance was set at p < 0.05.Fig. 1. XRD patterns of the non-foamed CPC and the SG-foam implants 4 weeks
after implantation compared with the intact bone.3. Results
3.1. Material handling during surgery
All surgeries were performed without any complications. Both
of the foams and the non-foamed cement could be rapidly
(<5 min) prepared under sterile conditions in the operating theater
without the need for special equipment. All the pastes were inject-
able as described previously for the laboratory conditions [7] and
exhibited good cohesion in vivo. None of the materials disinte-
grated after contact with blood.3.2. Setting reaction in vivo
According to the XRD analysis (Fig. 1), a-TCP had entirely
hydrolyzed into hydroxyapatite 4 weeks after implantation in the
SG-foam, whereas in the non-foamed CPC traces of unreacted
a-TCP were still visible. The broad and overlapped nature of the
peaks observed for both samples, the unfoamed CPC and the
SG-foam, accounted for the small size of the hydroxyapatite
crystals. This effect was even more prominent in the intact bone
sample, which exhibited a smaller crystallinity, associated to the
nanometric size of apatite crystals in bone.
3.3. Histological evaluation
3.3.1. Non-foamed CPC
The non-foamed CPC did not signiﬁcantly degrade during the
20-week implantation period (Figs. 2A–C and 4), with >90% of
the defect region still ﬁlled with the CPC (Figs. 2C and 4C). Only
at the implant edge did minor degradation occur, and a dense layer
of newly formed bone completely covered the cement surface,
indicating good biocompatibility and excellent osteointegration
(Fig. 3A). As expected, only a few small pores were visible in the
cement.
3.3.2. G-foam
In contrast, the G-foam was rapidly degraded, starting from the
edges of the implant (Figs. 2D–F and 4). Within 4 weeks, only
24 ± 11% of the defect area were ﬁlled with the material (Fig. 4A).
Many pores were visible in the remaining material, indicating that
its macroporous structure was maintained after injection and set-
ting (Fig. 3B). The degraded G-foam was completely replaced by
trabecular bone, which ﬁlled 33 ± 10% of the entire defect region
after 4 weeks (Fig. 4A). The remaining G-foam was located in the
center of the defect area and its outer pores were widely invaded
by bone tissue, thereby forming a dense bone–material transition
zone (Figs. 2D and 3B). We frequently observed osteoclast-like cells
degrading the material near the cement surface (Fig. 3C). The
newly formed bone contained much osteoid, indicating high met-
abolic activity.
Few material remnants remained at 12 and 20 weeks after
implantation in the center of the defect, and these were completely
Fig. 2. Histological images of bony implants. Upper row: non-foam CPC after 4 (A), 12 (B) and 20 (C) weeks; second row: G-foam after 4 (D), 12 (E) and 20 (F) weeks; third
row: SG-foam after 4 (G), 12 (H) and 20 (I) weeks; bottom row: subcutaneous implants after 20 weeks (J: CPC; K: G-foam; L: SG-foam). Paragon staining. Bars: 1000 lm.
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the interface (Figs. 2E and F and 3D and E). After 12 and 20 weeks,
the relative amount of bone in the defect area was 21 ± 10% and
25 ± 8%, respectively, thereby attaining the physiological trabecu-
lar bone density of intact bone at the same location (23 ± 9%).
The main part of the defect was ﬁlled with soft tissue, representing
normal bone marrow between the newly formed trabeculae
(Fig. 4B and C). No inﬂammatory reaction was observed at any time
point, indicating good biocompatibility (Fig. 3D and E). Very rarely
were single macrophages and foreign body giant cells found.
3.3.3. SG-foam
The SG-foam tended to exhibit a slower degradation rate com-
pared to the G-foam, with a signiﬁcantly lower degradation being
observed at 12 weeks (Figs. 2G–I and 4A–C). After 4 weeks,
39 ± 28% of the defect region were ﬁlled with material, with no sig-
niﬁcant difference compared to the G-foam (Fig. 4A), while after 12
and 20 weeks it was still 22 ± 17% and 30 ± 29%, respectively(Fig. 4B and C). Again, we found no signiﬁcant inﬂammatory reac-
tion and only rarely macrophages or foreign body giant cells, indi-
cating excellent biocompatibility (Fig. 3F and G).
The new trabecular bone in the surrounding of the SG-foam
appeared to be denser compared to the G-foam (Figs. 2G and H
and 3F). The amount of newly formed bone in the defect region
was not signiﬁcantly different from the defects treated with the
G-foam, whereas the soft tissue fraction, representing the bone
marrow between the bone trabeculae, was decreased, although
not signiﬁcantly, conﬁrming the observation of a higher bone den-
sity (Fig. 4). As in the G-foam-treated defects, the outer pores of the
SG-foam were invaded by bone tissue, thereby forming a dense
bone–material transition zone (Fig. 3F and G).
3.3.4. Subcutaneous implants
The subcutaneously implanted, pre-set cements were sur-
rounded by a soft tissue layer (Fig. 2J–L). Again, no inﬂammatory
reaction was observed. After 4 and 12 weeks, we observed no
Fig. 3. Histological images at higher magniﬁcations of bony (A–G, Giemsa staining) and subcutaneous implants (H–I; Giemsa staining). (A) CPC after 12 weeks; (B) G-foam
after 4 weeks; (C) osteoclast on foam particles (white arrow) in G-foam; (D) G-foam after 12 weeks; (E) G-foam after 20 weeks; (F) SG-foam after 4 weeks; (G) SG-foam after
20 weeks (remaining foam particles are embedded in the new bone); (H) subcutaneous G-foam implant (vessel formation is present (black arrow) and macrophages are on
the cement (white arrows)); (I) subcutaneous SG-foam implant (macrophage on the foam is marked with a white arrow). Bars: 100 lm (A–E, G and H) or 200 lm (F and I).
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were slightly degraded after 20 weeks (Fig. 2K), the SG-foams did
not signiﬁcantly resorb during this time (Fig. 2L). In contrast, in
both foams many pores were visible. The pores were ﬁlled with
connective tissue containing blood vessels and a few macrophages
and foreign body giant cells (Fig. 3H and I). No ectopic bone forma-
tion was observed in any of the subcutaneous implants at any time
point.3.4. Biomechanical results
The stiffness of non-foamed CPC did not signiﬁcantly change
during implantation and was considerably higher than that of the
intact trabecular bone at the same region (Fig. 5).
Because the new bone formed a composite with the residual
materials, both the bone and the materials could have contributed
to the mechanical performance in the defect area. After 4 weeks, at
which time point 75% of the G-foam was degraded, the stiffness
in the defect region was 1623 ± 478 N mm1 and in the range of
the physiological bone of the same region (1181 ± 504 N mm1)
(Fig. 5). The stiffness did not signiﬁcantly change over the implan-
tation period, when the G-foam was nearly completely replaced by
new bone (Fig. 5). At all implantation time points, the stiffness in
the defect region of the SG-foam-treated group was signiﬁcantly
greater compared to the G-foam-treated group and also signiﬁ-
cantly greater than that of the intact bone (3338 ± 1816,
3896 ± 1578 and 4058 ± 2112 N mm1 4, 12 and 20 weeks after
implantation, respectively). The stiffness of the SG-foam-treated
defects did not signiﬁcantly change during implantation (Fig. 5).
The stiffness of the non-foamed CPC cement measured in vitro
after 12 days in Ringer’s solution was 1574 ± 545 N mm1, and of
the G- and SG-foam 25 ± 6 N mm1 and 469 ± 110 N mm1,
respectively.4. Discussion
This study demonstrated that injectable macroporous gelatine-
based calcium phosphate foams could be used successfully for the
treatment of critical-size bone defects in rabbits. The foams main-
tained their macroporosity after injection and setting in vivo. Com-
pared to non-foamed CPC, cellular degradation was considerably
increased and accompanied by new bone formation. The additional
functionalization with soybean extract slightly reduced the degra-
dation rate of the foam and signiﬁcantly increased the mechanical
performance in the defect area. Furthermore, both foams exhibited
excellent biocompatibility, implying that the novel materials may
be promising for clinical application in non-loaded bone defects.
To introduce macroporosity and increase bioactivity, we used
gelatine and soybean extracts as additives in an a-TCP cement,
which converts into calcium-deﬁcient hydroxyapatite (CDHA) dur-
ing the setting reaction [16]. A great advantage of gelatine applica-
tion over other foaming agents is its osteostimulative properties.
The addition of gelatine improved the attachment and spreading
of osteoblastic cells on calcium phosphate in vitro [17,18] and
increased proliferation and osteogenic differentiation [19,20].
Our preceding in vitro studies demonstrated that the addition of
gelatine and soybean extract did not affect the conversion of a-TCP
to CDHA [7,21]. The XRD analysis in the present in vivo study
revealed that the a-TCP in the foams hydrolyzed almost entirely
to CDHA 1 month after implantation. Interestingly, the reaction
proceeded further in the foamed than in the unfoamed cements,
probably due to a higher exposure to the body ﬂuids as a result
of the higher porosity. This suggests that the foams also success-
fully hardened in the in vivo environment. In our previous studies,
we were able to demonstrate that the addition of gelatine and soy-
bean extracts considerably improved the cohesion and injectability
of the cement paste, and that the ﬁnal porosity, pore interconnec-
tivity and pore size could be modulated by the gelatine and
Fig. 4. Quantiﬁcation of the remaining material and of the tissue in the defect area after 4 (A), 12 (B) and 20 (C) weeks of implantation. All the data are presented as mean ± SD
(n = 6-7, ⁄p < 0.05).
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work [7], the size and spherical shape of the macropores obtained
were equivalent in the G- and SG-foam, being in the range of 10 to
20 lm. Furthermore, the foams were similar in terms of the open
macroporosity available for new bone ingrowth. The total open
porosity determined using mercury intrusion porosimetry was
65.0% and 62.4%, respectively, for the G- and SG-foam. Moreover,
the open macroporosity was 23.2% and 32.0%, respectively, with
a mean connection size of 20 lm for both foam types [7]. In con-
trast, the non-foamed CPC had no open macroporosity, with the45.7% porosity corresponding to pores <5 lm. Because of method-
ological reasons, we were unable to determine the porosity
quantitatively after explantation of samples in the present study.
However, we observed many pores in the remaining foams in the
histological slides 4 weeks after implantation, implying that the
foams maintained their macroporous structure after injection
and setting under in vivo conditions without disintegration or pore
collapse.
The introduction of macropores signiﬁcantly increased the
degradation rate of the CPC. Within 4 weeks, 76% and 61%,
Fig. 5. Stiffness of the defect zone in the different material groups 4, 12 and 20 weeks after implantation. All the data are presented as mean ± SD (n = 6-7, ⁄p < 0.05).
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imal amount of non-foamed CPC was resorbed even 20 weeks after
implantation. The higher degradation rate of the foams may result
from the greater accessibility of the material for degrading cells,
including osteoclasts, and blood vessels. Other authors developed
composites of CPC and gelatine microspheres, where the macropo-
rosity was achieved by passive dissolution of the gelatine in situ
[22,23]. However, because of the low diffusion of physiological ﬂu-
ids inside the cement, the macropores were formed only in the
periphery of the implant and bone ingrowth was limited to that
site [22]. In contrast, the macroporosity produced by the mechan-
ical foaming, as was the case of the foams tested in this study, is
widely available for cell colonization immediately from the time
of implantation. Indeed, we found newly formed bone deeply
penetrating the pores from the outside; however, the pores within
the center of the foams were not completely invaded after 4 weeks.
This suggests that the outer and inner macropores were not com-
pletely interconnected or that the pore size was not sufﬁciently
large to be entirely penetrated by tissue. However, we do not con-
sider this to be a disadvantage, because the timing of material deg-
radation and new bone formation was effectively synchronized in
both the G- and SG-foam.
Degradation of calcium-deﬁcient hydroxyapatite occurs mainly
by active cellular resorption and to a lesser extent through physical
dissolution [24]. Notably, the pre-set foams, which were subcuta-
neously implanted, degraded slowly compared to the orthotopic
implants, even when the pores were invaded by soft tissue, sug-
gesting that the degradation observed after orthotopic implanta-
tion was performed predominantly by bone-speciﬁc osteoclasts,
which could be observed near the foams. Osteoclasts are able to
resorb not only natural bone but also synthetic hydroxyapatite
by secreting H+ from their subcellular compartment, thus decreas-
ing the local pH [25,26]. In the subcutaneously implanted foams,
we only occasionally found macrophages and a few foreign body
giant cells degrading the material. The slower cellular degradation
of the SG-foam after orthotopic and ectopic implantation may be
due to the suppressive effect of isoﬂavones on monocytes/macro-
phages and osteoclasts [11]. This implies that soybean extracts
could be used to reduce the immune response and to modulate
the cellular degradation of biomaterials.
Both foams exhibited excellent biocompatibility and were com-
pletely replaced by bone. The new bone invaded the pores, thus
building a dense composite, and there was intimate contact to
the inner and outer surfaces of the foams. Other authors observed
poor osseointegration of pre-formed gelatin–hydroxyapatite com-
posites after implantation in the mandible of monkeys possiblydue to the less tight contact of the implant and host tissue by using
a pre-formed material instead of cement [27]. Liao et al. reported
even inﬂammatory reactions towards injectable calcium phos-
phate cements containing gelatin microspheres after implantation
of femoral condyles of rabbits [28]. However, the positive effect of
gelatine observed in the present study was conﬁrmed by other
in vivo studies demonstrating excellent osteointegration and bone
ingrowth in either cement [29] or pre-formed implants [30].
We expected that the enrichment of the foam with soybean
extract would stimulate bone formation, because phytoestrogens
are known to stimulate osteoblast proliferation and differentiation
[7,10,11]. The quantitative histological analysis showed that the
relative amount of newly formed bone in the defects treated with
the SG-foam was not signiﬁcantly different compared to the
G-foam, although we did observe that the bone was denser in
the surrounding of the SG-foam. This observation was further sup-
ported by the lower relative amount of bone marrow between the
bone trabeculae, which, however, did not reach statistical signiﬁ-
cance when compared to the G-foam. Nevertheless, these results
suggest an osteostimulative effect of soybean enrichment. These
results conﬁrm a previous paper of Giavaresi et al., who demon-
strated that soybean-based hydrogels promote bone formation in
a rabbit bone defect model [12]. Therefore, it can be suggested that
the functionalization with soybean extracts increases the bioactiv-
ity of bone ﬁllers, thus being an alternative to osteoinductive
growth factors.
The synchronized timing of bone formation and the degradation
of the foams led to an excellent mechanical performance in the
defect area. The compression tests demonstrated that the stiffness
of the G-foam-treated defects was already in the physiological
range of intact bone 4 weeks after implantation and was main-
tained until the material was completely degraded. The stiffness
was signiﬁcantly less compared to non-foamed CPC. This may be
an advantage in some clinical applications, including the treatment
of subchondral bone defects. There, the high stiffness of solid
cements is considered to negatively inﬂuence the subchondral
bone and the cartilage, thus increasing the risk of osteoarthritis
[31]. Interestingly, the SG-foam-treated defects exhibited a signif-
icantly higher stiffness compared to those of the G-foam. This may
result from the higher bone density observed in the histological
evaluation and, therefore, further supported our suggestion that
the addition of soybean extract may have an osteostimulative
effect. Because the new bone formed a composite with the
remaining foam, the foam could also inﬂuence the mechanical
properties in the defect area. The evaluation of samples hardened
in vitro showed that the initial stiffness of the foams was much
A. Kovtun et al. / Acta Biomaterialia 12 (2015) 242–249 249lower compared to non-foamed CPC, indicating that the foams may
not signiﬁcantly contribute to the mechanical performance of the
bone–material composite in the defect region, even if the
mechanical properties of the SG-foam are increased compared to
the G-foam [7]. This also suggests that the foams could only be
used in a non-loaded environment.
In a previous in vivo study, we used albumen as a foaming agent
for CPC and tested the resulting foam in a similar rabbit model [4].
Albumen resulted in a 675% porosity, and bone growth and neo-
vascularization were observed within the material pores. After
12 weeks of implantation, the residual material fraction in the
bone defect was 35% of the initial value, being within the range
of the SG-foam used in the present study. However, we observed
more macrophages and multinucleated cells, indicating a slight
immunogenic reaction, probably provoked by the albumen, and
the resorption rate was slightly more rapid than the bone ingrowth
[4]. The biological performance and the osteostimulation of the
gelatine-based foams used in the present study were clearly supe-
rior compared to our previously developed albumen-based foams.5. Conclusions
The results of the present study suggest that the macroporous
gelatine-based CPC foams, which were previously developed by
our group [7,21], exhibited excellent behavior when applied
in vivo in a rabbit model. They could be easily and rapidly prepared
in the operating theater and retained good injectability and cohe-
sion as determined in vitro [7], and maintained their macroporos-
ity under in vivo conditions. In addition, they were biocompatible,
degraded considerably more rapidly compared to non-foam CPC
and were synchronically replaced by newly formed bone. The
enrichment of the foam with soybean extracts appeared to support
bone formation, resulting in denser bone and increased mechanical
performance. Both foams may be suitable as injectable cements for
the treatment of non-loaded bone defects, but could be also used in
a pre-set form as porous scaffolds for tissue engineering.Acknowledgements
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Certain ﬁgures in this article, particularly Fig. 1 is difﬁcult to
interpret in black and white. The full colour images can be found
in the on-line version, at http://dx.doi.org/10.1016/j.actbio.
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